KCT0000928招募中未知
A multicenter, randomized, double blind study to compare the efficacy between cilostazol and aspirin on white matter changes by cerebral small vessel disease
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 238
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 85(Year)（—）
- 性别
- All
入选标准
- •50 to 85 years of age
- •-He/She can walk to the hospital (walker or cane is permissible).
- •-Cerebral small vessel disease is oberved on brain MRI.
- •1) presence of one or more lacunar infarction and 2) moderate or severe confluenct leukoaraiosis (defined as grade 2 or 3 on a modified Fazekas scale): periventricular WMCs with cap or rims lager than 5mm and deep subcortical WMCs >10 mm in maximum diameter
- •-written informed consent
排除标准
- •-Any patient with contraindication of antiplatelets
- •-Any patient with cardioembolic source
- •-Carotid bruit or large cerebral artery stenosis >50%
- •-Cortical infarction or subcortical infarction lager than 1.5 cm
- •-bleeding tendency
- •-chronic liver disease (AST or ALT >100 IL/L)
- •-chronic renal disease (Creatinine >3.0mg/dL)
- •-active gastrointestinal ulcer
- •-any patients with any severe or unstable medical disease that may prevent them from completing study requirements (i.e., unstable or severe asthma)
- •-Anemia (Hb <10g/dL) or thrombocytopenia
- •-Cardiac pacemaker or contraindication to MRI
- •-Pregnancy or breast-feeding
- •-drug or alcohol addiction
- •-Any other white matte disease (i.e., Multiple sclerosis, sarcoidosis, or brain irradiation, etc) or brain tumor
- •-Parkinson's disease, Alzheimer's disease or any other neurodegenerative disease
- •-any hearing or visual impairment that can disturb the efficient evaluation of the patient
- •-recent cerebral infarction with 3 months
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetesType II DiabetesEUCTR2005-000473-22-CZovartis Pharma Services AG344
进行中（未招募）
1 期
A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetesType II DiabetesMedDRA version: 7.1Classification code 10045242EUCTR2005-000473-22-SKovartis Pharma Services AG344
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapyType II DiabetesEUCTR2008-001246-21-PLovartis Pharma Services AG300
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.Study in patients with mixed dyslipidemia (type IIb) at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.MedDRA version: 9.1Level: LLTClassification code 10027763Term: Mixed hyperlipidemiaEUCTR2006-005851-14-LTFOURNIER LABORATORIES IRELAND Ltd1,945
进行中（未招募）
不适用
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.Study in patients with mixed dyslipidemia (type IIb) at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.MedDRA version: 9.1Level: LLTClassification code 10027763Term: Mixed hyperlipidemiaEUCTR2006-005851-14-EEFOURNIER LABORATORIES IRELAND Ltd1,945